Pay in 4 interest-free payments of $6.80 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
In this episode John and Professor Shah open with why insulin alone has structural limitations in type 1 diabetes, work through how GLP-1 therapies act on the body, and then walk the trial evidence from the early exenatide and liraglutide studies to the more recent semaglutide and tirzepatide data
Reducing these roadblocks can help peptide therapy work more effectively
[DOI] [PubMed] [Google Scholar] Miyawaki K, Yamada Y, Yano H, Niwa H, Ban N, Ihara Y, Kubota A, Fujimoto S, Kajikawa M, Kuroe A, et al
Lancet 393 , 434445 (2019)
Schedule a telehealth consultation with one of our local, trusted medical providers
The Metabolic Rationale for Stacking MOTS-c and 5-Amino-1MQ When you stack MOTS-c 5-Amino-1MQ, you're addressing two separate limiting factors in cellular energy metabolism that often coexist in metabolic dysfunction models: impaired substrate utilization and depleted cofactor availability
US$ 27.24
US$ 25.54
US$ 28.50
US$ 20.18
